504 related articles for article (PubMed ID: 19232036)
41. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH).
Oseroff O; Retyk E; Bochoeyer A
Curr Opin Cardiol; 2004 Jan; 19(1):26-30. PubMed ID: 14688631
[TBL] [Abstract][Full Text] [Related]
42. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.
Piccini JP; Berger JS; O'Connor CM
Eur Heart J; 2009 May; 30(10):1245-53. PubMed ID: 19336434
[TBL] [Abstract][Full Text] [Related]
43. Are implantable cardioverter- defibrillators cost-effective?
Naik AM; Peter CT
Curr Cardiol Rep; 2000 Jul; 2(4):341-5. PubMed ID: 10953269
[TBL] [Abstract][Full Text] [Related]
44. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
45. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
[TBL] [Abstract][Full Text] [Related]
46. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
[TBL] [Abstract][Full Text] [Related]
47. [Amiodarone or ICD in patients with cardiac insufficiency. SCD-HeFT Study].
Borggrefe M; Wolpert C
Internist (Berl); 2006 Jan; 47(1):89-91. PubMed ID: 16344952
[No Abstract] [Full Text] [Related]
48. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy.
Gold MR; Ip JH; Costantini O; Poole JE; McNulty S; Mark DB; Lee KL; Bardy GH
Circulation; 2008 Nov; 118(20):2022-8. PubMed ID: 18955671
[TBL] [Abstract][Full Text] [Related]
49. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Olshansky B; Wood F; Hellkamp AS; Poole JE; Anderson J; Johnson GW; Boineau R; Domanski MJ; Mark DB; Lee KL; Bardy GH;
Am Heart J; 2007 Jun; 153(6):1089-94. PubMed ID: 17540216
[TBL] [Abstract][Full Text] [Related]
50. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
51. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.
Levy WC; Hellkamp AS; Mark DB; Poole JE; Shadman R; Dardas TF; Anderson J; Johnson G; Fishbein DP; Lee KL; Linker DT; Bardy GH
JACC Clin Electrophysiol; 2018 Aug; 4(8):1089-1102. PubMed ID: 30139491
[TBL] [Abstract][Full Text] [Related]
52. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
53. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
Parkes J; Bryant J; Milne R
Health Technol Assess; 2000; 4(26):1-69. PubMed ID: 11086270
[TBL] [Abstract][Full Text] [Related]
54. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
[TBL] [Abstract][Full Text] [Related]
55. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
Schläpfer J; Rapp F; Kappenberger L; Fromer M
J Am Coll Cardiol; 2002 Jun; 39(11):1813-9. PubMed ID: 12039497
[TBL] [Abstract][Full Text] [Related]
56. The implantable cardioverter-defibrillator: does everybody need one?
Raj SR; Sheldon RS
Prog Cardiovasc Dis; 2001; 44(3):169-94. PubMed ID: 11727276
[TBL] [Abstract][Full Text] [Related]
57. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
58. [Primary prevention of sudden cardiac death implanted cardioverter defibrillator (ICD) versus antiarrhythmic drugs].
Iturralde Torres P
Arch Cardiol Mex; 2007; 77 Suppl 4():S4-129-32. PubMed ID: 18938711
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy.
Larsen GC; Manolis AS; Sonnenberg FA; Beshansky JR; Estes NA; Pauker SG
J Am Coll Cardiol; 1992 May; 19(6):1323-34. PubMed ID: 1564234
[TBL] [Abstract][Full Text] [Related]
60. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
Böcker D; Breithardt G
Am J Cardiol; 1999 Mar; 83(5B):83D-87D. PubMed ID: 10089846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
